GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Latest Information Update: 05 Feb 2021
At a glance
- Drugs Selvigaltin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Galecto Biotech
- 02 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment due to COVID-19 pandemic and change in the clinical development strategy for the GB1211 compound
- 17 Sep 2020 New trial record
- 15 Sep 2020 According to a Galecto media release, it will initiate this trial in Q4 2020 in patients with NASH to assess the effect of GB1211 on fibrosis-related biomarkers and other fibrosis endpoints.